27833-64-3

• 常用中文名：丁二酸洛沙平
• 常用英文名：Loxapine succinate
• CAS号：27833-64-3
• 分子式：C₂₂H₂₄ClN₃O₅
• 分子量：445.896
• 相关类别： 生物化工 抑制剂 神经信号通路(Neuronal Signaling) 5-HT Receptor 拮抗剂
• 发布时间：2018-03-22 08:00:00
• 更新时间：2026-07-02 12:38:14
• Loxapine琥珀酸盐是D2/D4多巴胺受体,5羟-色胺受体抑制剂。

名称

• 中文名: 丁二酸洛沙平
• 英文名: loxapine succinate
• 中文别名: 琥珀酸洛沙平,10 MM DMSO 溶液; 洛沙平琥珀酸酯; 丁二酸洛沙平, 一种5羟-色胺受体抑制剂, 多巴胺受体; 洛沙平琥珀酸盐; 2-氯-11-(4-甲基哌嗪-1-基)二苯并[B,F][1,4]氧杂氮杂卓丁二酸盐; 琥珀酸洛沙平; 丁二酸洛沙平 标准品; 丁二酸洛沙平.醋酸钠; 2-氯-11-(4-甲基哌嗪-1-基)二苯并[b,f][1,4]氧氮杂卓丁二酸盐
• 英文别名: 2-Chloro-11-(4-methylpiperazin-1-yl)dibenzo[b,f][1,4]oxazepine succinate (1:1); Succinic acid - 2-chloro-11-(4-methyl-1-piperazinyl)dibenzo[b,f][1,4]oxazepine (1:1); succinic acid, compound with 2-chloro-11-(4-methylpiperazin-1-yl)dibenz[b,f][1,4]oxazine (1:1); 6,9-Dihydro-2-chloro-11-(4-methylpiperazino)dibenz[b,f][1,4]oxazine; acide butanedioïque - 2-chloro-11-(4-méthylpipérazin-1-yl)dibenzo[b,f][1,4]oxazépine (1:1); MFCD00069298; Loxapine Succinate Capsules; Loxapine succina; loxitane; LOXAPINE SUCCINATE DIBENZOXAZINE ANTIP; 2-CHLORO-11-(4-METHYL-1-PIPERAZINYL)-DIBENZ[B,F][1,4]-OXAZINE SUCCINATE; Cloxazin; Oxilapine; Loxapine succinate solution; Loxapine succinate salt //BP; Dibenz[b,f][1,4]oxazepine, 2-chloro-11-(4-methyl-1-piperazinyl)-, butanedioate (1:1); CL-62362; butanedioic acid,8-chloro-6-(4-methylpiperazin-1-yl)benzo[b][1,4]benzoxazepine; 2-chloro-11-(4-methylpiperazin-1-yl)dibenzo[b,f][1,4]oxazepine butanedioate; Lederle; oxazine(1:1); 2-Chloro-11-(4-methyl-1-piperazinyl)dibenzo[b,f][1,4]oxazepine succinate; loxapac; dopamine rector; Loxapine (succinate); Butanedioic acid, compd. with 2-chloro-11-(4-methyl-1-piperazinyl)dibenz[b,f][1,4]oxazine (1:1); Loxapine.succinate, 1mg/ml in Methanol (as free base); Loxapine Succinate saltQ: What is Loxapine Succinate salt Q: What is the CAS Number of Loxapine Succinate salt Q: What is the storage condition of Loxapine Succinate salt; cl71563; LOXAPINE SUCCINATE SALT; LOXAPINE SUCCINATE; Daxolin; succinicacid,compd.with2-chloro-11-(4-methyl-1-piperazinyl)dibenz(b,f)(1,4)oxazine(1:1); Butandisäure--2-chlor-11-(4-methylpiperazin-1-yl)dibenzo[b,f][1,4]oxazepin(1:1); succinicacid,compd.with2-chloro-11-(4-methyl-1-piperazinyl)dibenz(b,f)(1,4); Loxitane; Loxapine succinate salt, 25 ade; Loxapac; EINECS 248-682-0; succinic acid 2-chloro-11-(4-methylpiperazin-1-yl)dibenz[b,f][1,4]oxazine salt; Calcium Cbonate Tablets; lederle; Loxapine succinate, 10 mM in DMSO; loxapine succinate salt; Lidocaine succinate a 5-HT inhibitor; S-805; Cloxazepin; Loxapine succinate, >=; daxoline; 8-chloro-6-(4-methyl-1-piperazin-1-iumylidene)-5H-benzo[b][1,4]benzoxazine; SUM-3170; SUM-317; LIDOCAINE SUCCINATE; LOXAPINESUCCINATE

物化性质

• 沸点: 458.6ºC at 760mmHg
• 熔点: 150-152°C
• 分子式: C₂₂H₂₄ClN₃O₅
• 分子量: 445.896
• 闪点: 231.1ºC
• 精确质量: 445.140442
• PSA: 102.67000
• LogP: 3.01860
• 外观性状: 白色固体
• 储存条件: -20°C Freezer
• 水溶解性: H2O: soluble
• 计算化学:

  1.疏水参数计算参考值（XlogP）:无

  2.氢键供体数量:2

  3.氢键受体数量:7

  4.可旋转化学键数量:4

  5.互变异构体数量:无

  6.拓扑分子极性表面积103

  7.重原子数量:31

  8.表面电荷:0

  9.复杂度:542

  10.同位素原子数量:0

  11.确定原子立构中心数量:0

  12.不确定原子立构中心数量:0

  13.确定化学键立构中心数量:0

  14.不确定化学键立构中心数量:0

  15.共价键单元数量:2

• 更多:

  1. 性状：白色固体

  2. 密度（g/mL,25/4℃）：未确定

  3. 相对蒸汽密度（g/mL,空气=1）：未确定

  4. 熔点（ºC）：150-152

  5. 沸点（ºC,常压）：未确定

  6. 沸点（ºC,5.2kPa）：未确定

  7. 折射率：未确定

  8. 闪点（ºC）：未确定

  9. 比旋光度（º）：未确定

  10. 自燃点或引燃温度（ºC）：未确定

  11. 蒸气压（kpa,20ºC）：未确定

  12. 饱和蒸气压（kPa,60ºC）：未确定

  13. 燃烧热（KJ/mol）：未确定

  14. 临界温度（ºC）：未确定

  15. 临界压力（KPa）：未确定

  16. 油水（辛醇/水）分配系数的对数值：未确定

  17. 爆炸上限（%,V/V）：未确定

  18. 爆炸下限（%,V/V）：未确定

  19. 溶解性：溶于水

生物活性

• 描述: Loxapine琥珀酸盐是D2/D4多巴胺受体,5羟-色胺受体抑制剂。
• 相关类别:
  信号通路 >> G 蛋白偶联受体/G 蛋白 >> 5-HT受体
  信号通路 >> 神经信号通路 >> 5-HT受体
  研究领域 >> 神经疾病
• 参考文献:

  [1]. Singh AN, et al. A neurochemical basis for the antipsychotic activity of loxapine: interactions with dopamine D1, D2, D4 and serotonin 5-HT2 receptor subtypes. J Psychiatry Neurosci. 1996 Jan;21(1):29-35.

  [2]. Labuzek K, et al. Chlorpromazine and loxapine reduce interleukin-1beta and interleukin-2 release by rat mixed glial and microglial cell cultures. Eur Neuropsychopharmacol. 2005 Jan;15(1):23-30.

  [3]. Lee T, et al. Loxapine and clozapine decrease serotonin (S2) but do not elevate dopamine (D2) receptor numbers in the rat brain. Psychiatry Res. 1984 Aug;12(4):277-85.

  [4]. Kalkman HO, et al. Clozapine inhibits catalepsy induced by olanzapine and loxapine, but prolongs catalepsy induced by SCH 23390 in rats. Naunyn Schmiedebergs Arch Pharmacol. 1997 Mar;355(3):361-4.

毒性和生态

毒理学数据: 急性毒性：女性口经TDL：6 mg/kg/2D-I CHEMICAL IDENTIFICATION RTECS NUMBER : WM5750000 CAS REGISTRY NUMBER : 27833-64-3 LAST UPDATED : 198910 DATA ITEMS CITED : 3 MOLECULAR FORMULA : C18-H18-Cl-N3-O.C4-H6-O4 MOLECULAR WEIGHT : 445.94 WISWESSER LINE NOTATION : T C676 BO INJ MG J- AT6N DNTJ D1 &QV2VQ HEALTH HAZARD DATA ACUTE TOXICITY DATA TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Oral SPECIES OBSERVED : Human - woman DOSE/DURATION : 6 mg/kg/2D-I TOXIC EFFECTS : Behavioral - toxic psychosis REFERENCE : JCLPDE Journal of Clinical Psychiatry. (Physicians Postgraduate Press, Inc., POB 240008, Memphis, TN 38124) V.39- 1978- Volume(issue)/page/year: 44,37,1983 TYPE OF TEST : LDLo - Lowest published lethal dose ROUTE OF EXPOSURE : Oral SPECIES OBSERVED : Human - woman DOSE/DURATION : 30 mg/kg TOXIC EFFECTS : Behavioral - convulsions or effect on seizure threshold Behavioral - coma Lungs, Thorax, or Respiration - chronic pulmonary edema REFERENCE : CTOXAO Clinical Toxicology. (New York, NY) V.1-18, 1968-81. For publisher information, see JTCTDW. Volume(issue)/page/year: 14,181,1979 TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Oral SPECIES OBSERVED : Human - woman DOSE/DURATION : 27 mg/kg/9D-I TOXIC EFFECTS : Endocrine - hyperglycemia REFERENCE : JCLPDE Journal of Clinical Psychiatry. (Physicians Postgraduate Press, Inc., POB 240008, Memphis, TN 38124) V.39- 1978- Volume(issue)/page/year: 44,347,1983

安全

• 个人防护装备: Eyeshields;Gloves;type N95 (US);type P1 (EN143) respirator filter
• 危害码 (欧洲): Xi
• 危险品运输编码: UN 2811 6.1 / PGII
• WGK德国: 3
• RTECS号: WM5750000